Shaping effective launch strategies in a crowded market
For years, oncology drug launches relied on standardized approaches. But tightening price controls, fiercer competition, and fast-evolving markets are challenging this model. Creating sustainable value now requires moving beyond one-size-fits-all. Oncology commercial organizations must embrace an archetype-driven mindset, using guiding models to tailor launch strategies and redesign go-to-market approaches. This shift is key to unlocking long-term success in an increasingly complex oncology landscape.
The dynamics of oncology are shifting rapidly, underpinned by a decade of unparalleled R&D investment from leading pharmaceutical players. Between 2020–2024, the top 10 oncology players increased their R&D spend at a +9.4% CAGR, surpassing US $125 billion (see Figure 1). This investment swelled oncology pipelines to record levels, with oncology now representing 41% of Phase II assets globally. Particularly striking is the rise of orphan drugs: more than 10% of oncology assets in development now target rare cancers, reflecting scientific progress and a strategic focus on high-value niches.
This transformation is also being driven by small and midsize biotech companies. They’re responsible for about two-thirds of innovative molecules and are setting the pace with agile R&D models. This has forced large incumbents to rely heavily on mergers, acquisitions, and licensing agreements to secure promising assets, especially late-stage compounds close to launch. As a result, pipelines are larger and more diverse, spanning multiple indications, tumor types, and geographies.
This innovation surge is reshaping the launch environment. Multi-indication development strategies are becoming the norm as companies seek to leverage a single asset across several therapeutic areas. This creates opportunities for faster scaling but compounds the complexity of launches: regulatory requirements, market-access pathways, and clinical narratives must be tailored for each indication. The pace of scientific discovery — accelerated by AI, biomarker-driven research, and adaptive trial designs — is making time-to-market a critical differentiator.
Simultaneously, external stakeholders are reshaping their expectations. Regulators and payers demand stronger evidence of value, patients are increasingly empowered and better informed, and healthcare systems under budgetary strain are less tolerant of high prices without demonstrated benefits. Oncology companies must navigate not only scientific and operational challenges but also shifting societal and economic pressures.
In this context, traditional launch playbooks (designed for slower, more predictable markets) are no longer fit for purpose. Success requires a shift in how companies prepare, execute, and sustain oncology launches.
Regulatory shifts, political and economic pressures, and intensifying competition are converging to test the resilience of traditional launch approaches.
Regulators around the world are reshaping the pace of oncology launches. In 2024, 18 of the 24 US Food and Drug Administration’s (FDA) new drug approvals (75%) leveraged expedited programs such as Fast Track, Breakthrough Therapy, Priority Review, or Accelerated Approval. More broadly, between 2015–2022, about 65% of FDA approvals benefited from priority review, and 57% had at least one accelerated designation. Therapies following these pathways typically reached the market one to two years faster than drugs without expedited status (~7.0 versus 8.3 years from development to approval). While the pace of drug approvals has accelerated in the US, Europe continues to move more slowly. Between 2010–2019, the FDA approved 95% of 89 oncology therapies before European Medicines Agency (EMA) authorization, with a median delay of 241 days on the European side. These dynamics create valuable opportunities to deliver innovation faster, but they compress the preparation window. Companies must ready their commercial engines earlier (often with incomplete clinical data) and align cross-functional teams in record time. What was once a carefully phased process now resembles a sprint, putting marketing execution, provider engagement, and organizational resilience under extreme pressure.
Oncology, once relatively shielded from deep pricing scrutiny, has become the epicenter of cost containment. The US Inflation Reduction Act (IRA) empowers Medicare to negotiate prices, sharply reducing the post-launch revenue horizon, imposing penalties for price increases above inflation, and capping patient out-of-pocket costs.
The first 10 drugs selected for negotiation are expected to generate nearly $6 billion in savings in the first year of implementation, underscoring the potential impact on manufacturers. In Europe, agencies such as Germany’s IQWiG (Institute for Quality and Efficiency in Health Care) and Italy’s AIFA (Italian Medicines Agency) are demanding greater transparency on R&D and production costs, pushing strongly for value-based pricing. A recent ISPOR (International Society for Pharmacoeconomics and Outcomes Research) analysis showed that at launch, the average ex-factory price of oncology therapies in the EU4 and the UK was about 0.69 times the US list price (wholesale acquisition cost); in more than 80% of cases, US launch prices were at least 10% higher than their European equivalents. These dynamics highlight how international reference pricing and health technology assessment (HTA) frameworks increasingly constrain oncology margins. This environment forces companies to embed evidence generation directly into launch planning. Without comparative data, real-world outcomes, and credible health economics, market access can be delayed, reimbursement restricted, or prices aggressively cut.
Roughly 70%-75% of oncology indications already feature multiple compounds either approved or in active development. Trial activity continues at a remarkable pace: in 2023, oncology accounted for nearly 30% of all global clinical trial starts, with more than 2,000 new oncology studies initiated (~10% more than in 2019). The flow of novel products shows no signs of slowing, with an average of 26 new active substance launches per year between 2020 and 2024, compared with roughly 16 in the preceding five years, and 25 oncology launches recorded in 2024 alone.
Biotechs drive speed and scientific novelty while large pharma leverages scale through alliances and acquisitions. This saturation drastically reduces the ability of any single product to dominate a therapeutic space for long. Differentiation is harder to secure, with competitors rapidly introducing similar action mechanisms or incremental advantages in safety, biomarkers, or convenience that influence prescriber and patient choices. In this crowded field, success is determined by robust clinical data and the capacity to achieve rapid penetration, establish credibility with stakeholders, and articulate a compelling value narrative.
To overcome these challenges, oncology companies must move beyond traditional approaches and embrace a tailored, agile, evidence-driven launch model based on:
Organizational design is a critical determinant of launch readiness. Companies face a choice between building cross-therapeutic-enabling functions or outsourcing noncore activities. In 2024, Arthur D. Little (ADL) conducted a study that analyzed organizational models across selected areas. It compared EU subsidiaries of multinational pharma groups and biotech startups operating in the oncology therapeutic area to understand how various companies organize themselves to manage specific business processes.
The main takeaways from the study are:
The right model depends on company size, portfolio maturity, and market complexity. This much is clear, however: fragmented, siloed organizations cannot sustain the pace of today’s oncology launches. Agile governance, rapid decision-making, and cross-functional coordination are essential.
One-size-fits-all strategies are no longer viable. An archetype-driven framework lets companies tailor go-to-market strategies based on key dimensions: type of product (new molecule vs. new indication), disease awareness, competitive intensity, and market maturity. By mapping launches against these archetypes, companies can more effectively allocate resources, set realistic timelines, and define the right engagement model. ADL’s Launch Excellence Archetype Matrix provides a structured approach to this process (see Figure 2).
This approach helps companies avoid overinvesting in launches that require a leaner model and under-resourcing those that demand significant up-front engagement. It also creates consistency across launches, providing common references that facilitate learning and knowledge transfer. An archetype-driven model helps companies move away from generic strategies and tailor their actions to the specific characteristics of each launch.
The first distinction is the type of drug: is it a new molecule or a new indication? This choice shapes the go-to-market model and must be aligned with country-specific market-access opportunities.
Equally important is the nature of the target audience: are companies engaging with a new stakeholder base or an established one? The answer will determine the level of marketing effort and the scale of field force deployment required.
Each launch carries its own opportunities, risks, and timelines. Attempting to manage this diversity through a single, standardized framework is inefficient and costly, jeopardizing launch success. Instead, preparatory activities (e.g., scope, resource gathering, timeline determination) should be adjusted to the archetype.
Notably, adopting an archetype-driven approach is not enough. It must be supported by practical tools and methods that enable seamless execution so that strategic objectives are converted into tangible results.
Provider engagement is undergoing a fundamental transformation. The number of field reps has declined, and physician time is increasingly constrained. Digital channels have proliferated, reshaping how information flows. At the same time, decision-making in oncology care is broader, involving nurses, pharmacists, payers, and patient advocates. To succeed, companies must broaden their engagement model. Field representatives should transition into key account managers capable of orchestrating multidisciplinary strategies at the hospital and oncology center level.
Engagement should be multichannel, blending face-to-face with digital and social platforms. Companies must engage the full ecosystem of patients, caregivers, and advocacy groups, acknowledging their growing influence in treatment decisions. This shift requires new skills, better data, and closer alignment between medical, commercial, and market-access functions. It also requires investments in training and change management to ensure that field teams can successfully engage with the entire ecosystem.
Digital capabilities are no longer optional; they determine the success or failure of the launch. Advanced analytics and AI can be used to optimize provider segmentation, predict patient populations, and forecast uptake scenarios. Digital platforms enhance omnichannel marketing, helping companies deliver targeted, timely messages across multiple channels.
Equally important is the patient dimension. Oncology patients increasingly rely on online communities, advocacy groups, and digital resources to make informed decisions. Companies that develop robust patient-support programs integrated with digital tools see greater differentiation, improved adherence, and enhanced brand equity. Caregivers, in particular, are essential stakeholders who can be meaningfully engaged through tailored digital resources. Finally, social media listening and digital monitoring of key opinion leaders and associations can provide invaluable insights for campaign design, and the ability to integrate these insights into launch planning is becoming a core competitive advantage.
Case study: A redesigned launch model for breast cancer therapy
A leading international pharmaceutical company aimed to reenter the breast cancer therapeutic landscape with an innovative portfolio designed to improve patient outcomes. Facing tight timelines and fierce competitive pressure, the company needed to rework its launch approach. Its new model focused on: (1) defining a tailored strategy aligned with the product’s clinical profile, (2) optimizing its salesforce deployment through improved territory mapping and provider profiling, and (3) integrating digital tools to enable data-driven decisions. This resulted in several successful launches that exceeded performance expectations and established a strong foundation for future portfolio expansion.
In today’s hypercompetitive oncology drug market, launch excellence requires agility, precision, and differentiation. Companies that succeed are doing so by changing how they prepare for and execute each launch. They are:
By Fabrizio Mineo, Robert Albarano, Laurent Dubalen, Ron Kwok, Giacomo Maria Sorricchio di Valforte
cloud technology axon
The building, for which planning permission has already been granted, ...
